• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

前列腺特异性抗原水平等于或低于4 ng/ml患者活检中前列腺癌的预测因素

Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml.

作者信息

Kim Hyoung Woo, Ko Young Hwii, Kang Seok Ho, Lee Jeong Gu

机构信息

Department of Urology, Sahmyook Medical Center, Seoul, Korea.

出版信息

Korean J Urol. 2011 Mar;52(3):166-71. doi: 10.4111/kju.2011.52.3.166. Epub 2011 Mar 18.

DOI:10.4111/kju.2011.52.3.166
PMID:21461279
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3065127/
Abstract

PURPOSE

This study was conducted to identify the predictive factors for prostate cancer in patients with prostate-specific antigen (PSA) levels equal to or less than 4 ng/ml.

MATERIALS AND METHODS

A retrospective study of medical records was conducted on 292 patients with initial serum PSA ≤4 ng/ml among 2,305 patients who underwent prostate biopsy from January 2003 to December 2008. Prostate biopsy was performed on patients with PSA ≤4 ng/ml in the case of abnormal findings in the digital rectal examination (DRE) or transrectal ultrasonography (TRUS) or in those with a PSA level higher than the age-adjusted PSA levels. The patients were divided into the group diagnosed with prostate cancer and the non-prostate-cancer group. Subsequently, the variables of the two groups were compared.

RESULTS

The patients' mean age was significantly higher in the prostate cancer group (n=28) than in the non-prostate-cancer group (n=264; p=0.033). In addition, for the patients with a PSA range of 2.0-2.9 ng/ml, their age (p=0.049) and PSA density (PSAD; p=0.042) were significantly higher and the prostate volume (p=0.028) was significantly smaller in the prostate cancer group than in the non-prostate-cancer group.

CONCLUSIONS

Of the patients with PSA ≤4 ng/ml, the age of the patients who showed abnormal findings in the DRE or TRUS or who had a PSA level higher than the age-adjusted PSA level was a significant predictive factor for prostate cancer. In particular, for the PSA range of 2.0-2.9 ng/ml, a thorough screening test for prostate cancer was required if the patients had conditions such as higher age, smaller prostate, and higher PSAD.

摘要

目的

本研究旨在确定前列腺特异性抗原（PSA）水平等于或低于4 ng/ml的患者中前列腺癌的预测因素。

材料与方法

对2003年1月至2008年12月接受前列腺活检的2305例患者中的292例初始血清PSA≤4 ng/ml的患者进行病历回顾性研究。对于直肠指检（DRE）或经直肠超声检查（TRUS）有异常发现或PSA水平高于年龄校正PSA水平的PSA≤4 ng/ml的患者进行前列腺活检。将患者分为前列腺癌诊断组和非前列腺癌组。随后，比较两组的变量。

结果

前列腺癌组（n = 28）患者的平均年龄显著高于非前列腺癌组（n = 264；p = 0.033）。此外，对于PSA范围为2.0 - 2.9 ng/ml的患者，前列腺癌组的年龄（p = 0.049）和PSA密度（PSAD；p = 0.042）显著更高，前列腺体积（p = 0.028）显著更小。

结论

在PSA≤4 ng/ml的患者中，DRE或TRUS有异常发现或PSA水平高于年龄校正PSA水平的患者年龄是前列腺癌的重要预测因素。特别是对于PSA范围为2.0 - 2.9 ng/ml的患者，如果患者有年龄较大、前列腺较小和PSAD较高等情况，则需要进行全面的前列腺癌筛查试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c73e/3065127/7a92952c0568/kju-52-166-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c73e/3065127/7a92952c0568/kju-52-166-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c73e/3065127/7a92952c0568/kju-52-166-g001.jpg

相似文献

1
Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml.前列腺特异性抗原水平等于或低于4 ng/ml患者活检中前列腺癌的预测因素
Korean J Urol. 2011 Mar;52(3):166-71. doi: 10.4111/kju.2011.52.3.166. Epub 2011 Mar 18.
2
Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.前列腺癌的检测：超声引导下经直肠超声检查（TRUS）、TRUS引导下活检、直肠指检、前列腺特异性抗原（PSA）及PSA密度的作用
J Exp Clin Cancer Res. 2001 Dec;20(4):473-80.
3
Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.具有成本效益的前列腺癌检测。减少低收益活检。美国癌症协会国家前列腺癌检测项目的研究人员。
Cancer. 1994 Dec 15;74(12):3146-58. doi: 10.1002/1097-0142(19941215)74:12<3146::aid-cncr2820741214>3.0.co;2-z.
4
[Examination for indication of systematic biopsy for diagnosis of prostate cancer].[用于前列腺癌诊断的系统活检指征检查]
Nihon Hinyokika Gakkai Zasshi. 1999 Jul;90(7):657-62. doi: 10.5980/jpnjurol1989.90.657.
5
Early detection of prostate cancer in the ESRD population.终末期肾病患者群体中前列腺癌的早期检测
Clin Nephrol. 2004 May;61(5):308-15. doi: 10.5414/cnp61308.
6
An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density.一种利用前列腺特异性抗原和前列腺特异性抗原密度在患者群体中检测前列腺癌的算法。
World J Urol. 1993;11(4):206-13. doi: 10.1007/BF00185070.
7
The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.筛查试验在前列腺癌检测中的价值。第二部分：游离/总前列腺特异性抗原分析比值、年龄特异性参考范围及前列腺特异性抗原密度的回顾性分析
Urology. 1995 Dec;46(6):779-84. doi: 10.1016/S0090-4295(99)80343-4.
8
The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer.在前列腺癌低发国家中，血清前列腺特异性抗原（PSA）水平处于中等的患者中，PSA密度的效用。
Urology. 1998 May;51(5A Suppl):125-30. doi: 10.1016/s0090-4295(98)00066-1.
9
Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.前列腺特异性抗原及前列腺特异性抗原密度与前列腺活检结果的相关性
Urology. 1994 Feb;43(2):191-6. doi: 10.1016/0090-4295(94)90043-4.
10
Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.在一个前列腺癌发病率较低的国家，使用血清前列腺特异性抗原（PSA）水平和PSA密度（PSAD）检测前列腺恶性肿瘤的原理。
Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:563-70.

引用本文的文献

1
CD44 rs13347C>T Variants in 3'UTR and Prostate Neoplasms: A Case-control Study and Bioinformatics Approach.3'非翻译区的CD44 rs13347C>T变异与前列腺肿瘤：一项病例对照研究及生物信息学方法
Int J Mol Cell Med. 2023;12(3):275-287. doi: 10.22088/IJMCM.BUMS.12.3.275.
2
Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?前列腺特异性抗原波动：在前列腺癌诊断中意味着什么？
Int Braz J Urol. 2015 Mar-Apr;41(2):258-64. doi: 10.1590/S1677-5538.IBJU.2015.02.11.
3
Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer.

本文引用的文献

1
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
2
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.在经直肠超声引导下前列腺活检中，当前列腺特异性抗原值在2.0至9.0 ng/mL之间时，前列腺体积是癌症诊断的最强预测指标。
Urology. 2007 Jan;69(1):103-7. doi: 10.1016/j.urology.2006.09.041.
3
Rising prostate cancer rates in South Korea.韩国前列腺癌发病率上升。
疑似前列腺癌的印度尼西亚人群中前列腺特异性抗原和前列腺特异性抗原密度的截断值。
Prostate Int. 2013;1(1):23-30. doi: 10.12954/PI.12003. Epub 2013 Jan 31.
4
DNA methylation of GSTP1 in human prostate tissues: pyrosequencing analysis.人前列腺组织中GSTP1的DNA甲基化：焦磷酸测序分析
Korean J Urol. 2012 Mar;53(3):200-5. doi: 10.4111/kju.2012.53.3.200. Epub 2012 Mar 19.
5
Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen?对于前列腺特异性抗原水平极高的老年患者，前列腺活检对于诊断前列腺癌是否必不可少？
Korean J Urol. 2012 Feb;53(2):82-6. doi: 10.4111/kju.2012.53.2.82. Epub 2012 Feb 20.
6
Prostate Cancer Can Be Detected Even in Patients with Decreased PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis.即使在慢性前列腺炎治疗后前列腺特异性抗原（PSA）低于2.5 ng/ml的患者中，也能检测出前列腺癌。
Korean J Urol. 2011 Jul;52(7):457-60. doi: 10.4111/kju.2011.52.7.457. Epub 2011 Jul 24.
Prostate. 2006 Sep 1;66(12):1285-91. doi: 10.1002/pros.20419.
4
Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.前列腺特异性抗原（PSA）低于4.0 ng/mL的前列腺癌的检出率及生物学意义：蒂罗尔筛查项目的观察结果及临床启示
Urology. 2005 Nov;66(5):1029-33. doi: 10.1016/j.urology.2005.05.025.
5
Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.直肠指检异常且血清前列腺特异性抗原低于4.0 ng/mL的患者中的前列腺癌。
Urology. 2005 Oct;66(4):803-7. doi: 10.1016/j.urology.2005.04.058.
6
The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.前列腺特异性抗原（PSA）与前列腺体积之比（PSA密度）作为一项参数，用于提高对PSA值在<4 ng/mL范围内前列腺癌的检测。
Cancer. 2005 Sep 1;104(5):993-1003. doi: 10.1002/cncr.21267.
7
Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.术前血清前列腺特异性抗原水平正常的男性行根治性前列腺切除术后的生化结果。
Cancer. 2004 Aug 15;101(4):748-53. doi: 10.1002/cncr.20390.
8
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.前列腺特异性抗原水平≤4.0纳克/毫升的男性中前列腺癌的患病率。
N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918.
9
Update on screening for prostate cancer with prostate-specific antigen.前列腺特异性抗原用于前列腺癌筛查的最新进展。
Crit Rev Oncol Hematol. 2004 Apr;50(1):71-8. doi: 10.1016/j.critrevonc.2003.11.001.
10
Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.在日本人群中，前列腺特异性抗原水平为2.0至4.0 ng/mL的男性中前列腺癌的检测情况与前列腺特异性抗原水平为4.1至10.0 ng/mL的男性相当。
Urology. 2004 Apr;63(4):727-31. doi: 10.1016/j.urology.2003.11.025.